Epcoritamab Plus R-mini-CHOP: A Potential Game-Changer for Elderly Patients with First-Line DLBCL
Deep Responses with Manageable Safety in High-Risk Elderly Patients
A groundbreaking study has revealed that a novel treatment combination, epcoritamab plus R-mini-CHOP, could revolutionize the treatment of elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). This combination therapy demonstrated remarkable efficacy and tolerability in a high-risk patient population, offering a glimmer of hope for those who have historically faced suboptimal outcomes.
Key Findings:
- Deep and Rapid Responses: The study, presented at the 2025 ASH Annual Meeting, showcased an overall response rate (ORR) of 93% in 28 patients, with an impressive complete response (CR) rate of 86%.
- Durability: At a median follow-up of 33.4 months, 79% of patients maintained their response, and 79% remained in CR, indicating the long-term efficacy of this treatment.
- Minimal Residual Disease (MRD) Negativity: An astonishing 95% of patients achieved MRD negativity, suggesting a significant reduction in cancer cells, which is a crucial indicator of treatment success.
- Safety Profile: Most adverse effects were mild to moderate, with no new safety concerns emerging with longer follow-up. The most frequent grade 3 or higher treatment-emergent adverse effects were neutropenia (43%), serious infections (32%), and anemia (14%).
Why Add Epcoritamab to R-mini-CHOP?
Dr. Chan Cheah, a leading expert in the field, explains that R-mini-CHOP, the standard of care for high-risk patients, often falls short in terms of outcomes. Epcoritamab, a CD3xCD20 bispecific antibody, has previously demonstrated efficacy when used as a monotherapy or in combination with standard treatments. The addition of epcoritamab to R-mini-CHOP resulted in an ORR of 89% and a CR rate of 82% in elderly patients with newly diagnosed DLBCL who couldn't tolerate full-dose R-CHOP.
The EPCORE NHL-2 Trial:
This open-label, phase 1b/2 trial enrolled patients with newly diagnosed DLBCL, including various subtypes. The treatment regimen involved a fixed duration of subcutaneous epcoritamab and intravenous R-mini-CHOP. The primary endpoint was ORR, and secondary endpoints included CR rate, MRD negativity, and safety.
Baseline Characteristics:
The median patient age was 81 years, with most patients (96%) over 75 years old and ineligible for full-dose anthracycline due to age, hypertension, diabetes, or a history of myocardial infarction. The majority had elevated lactate dehydrogenase levels and bulky tumors.
Safety Profile:
The safety profile was generally favorable, with most adverse effects being mild to moderate. The most common treatment-emergent adverse effects were neutropenia, serious infections, and anemia. Cytokine release syndrome (CRS) occurred in 61% of patients, but it was manageable with appropriate treatment.
Significance of Updated Data:
Dr. Cheah emphasizes the encouraging outcomes, especially in an older patient population. The study supports the potential of epcoritamab in combination with standard care across various disease settings and patient populations, offering a promising treatment option for those with historically poor outcomes.
